Literature DB >> 18973394

Topical treatments for scalp psoriasis.

Richard B Warren1, Benjamin C Brown, Christopher E M Griffiths.   

Abstract

Psoriasis is a common, chronic inflammatory skin disease that affects the scalp more commonly than any other site. Scalp psoriasis causes significant psychosocial disability as it is highly visible and can, on occasion, extend onto the face. Furthermore, current treatment regimens are messy, time consuming and, in some instances, ineffective, leading to a high level of non-compliance. The majority of current evidence for topical treatments for this condition comes from open-label, uncontrolled studies. From such studies, there are data to support the use of topical corticosteroids in a number of different formulations and topical vitamin D analogues. However, these studies have not addressed issues such as the need for keratolytics, which may be required to remove adherent scale before a topical corticosteroid or vitamin D analogue may prove efficacious. There is an urgent need for well designed, controlled trials to assess the efficacy of existing and new treatment regimens for scalp psoriasis. The aim of this review is to critically assess the relative effectiveness and tolerability of available topical therapies for this problematic condition and provide recommendations for selection of treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973394     DOI: 10.2165/0003495-200868160-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  64 in total

Review 1.  A systematic review of treatments for severe psoriasis.

Authors:  C E Griffiths; C M Clark; R J Chalmers; A Li Wan Po; H C Williams
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

2.  Scarring alopecia and psoriasis.

Authors:  P C van de Kerkhof; A Chang
Journal:  Br J Dermatol       Date:  1992-05       Impact factor: 9.302

3.  Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product.

Authors:  Nicoletta Cassano; Gino A Vena
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

4.  Histopathology of psoriasis treated with zinc pyrithione.

Authors:  C G Rowlands; F W Danby
Journal:  Am J Dermatopathol       Date:  2000-06       Impact factor: 1.533

5.  Regional variation in percutaneous penetration of 14C cortisol in man.

Authors:  R J Feldmann; H I Maibach
Journal:  J Invest Dermatol       Date:  1967-02       Impact factor: 8.551

6.  Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry.

Authors:  J Faergemann; I M Bergbrant; M Dohsé; A Scott; G Westgate
Journal:  Br J Dermatol       Date:  2001-03       Impact factor: 9.302

7.  Long-term treatment of psoriasis with calcipotriol scalp solution and cream.

Authors:  L Barnes; P Altmeyer; L Fôrstrôm; M H Stenström
Journal:  Eur J Dermatol       Date:  2000 Apr-May       Impact factor: 3.328

8.  Efficacy of a new antidandruff thermophobic foam: a randomized, controlled, investigator-blinded trial vs. ketoconazole 2% scalp fluid.

Authors:  G Quadri; W Cavallero; M Milani
Journal:  J Cosmet Dermatol       Date:  2005-01       Impact factor: 2.696

9.  Mutagenicity of urine from psoriatic patients undergoing treatment with coal tar and ultraviolet light.

Authors:  L A Wheeler; M D Saperstein; N J Lowe
Journal:  J Invest Dermatol       Date:  1981-08       Impact factor: 8.551

10.  A double-blind randomized vehicle-controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs. antidandruff efficacy and antimycotic activity.

Authors:  P Bailey; C Arrowsmith; K Darling; J Dexter; J Eklund; A Lane; C Little; B Murray; A Scott; A Williams; D Wilson
Journal:  Int J Cosmet Sci       Date:  2003-08       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.